drugset / Trial / NCT06365762

The Safety and Efficacy Study of Ethylenediaminetetraacetic Acid (EDTA) Ophthalmic Solution in Patients With Loss of Contrast Sensitivity Due to Age-Related, Low-Grade Nuclear Cataract

NCT06365762 ↗

Phase 1/2 Completed 111 enrolled Livionex Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The study objectives were: * To evaluate the efficacy of EDTA 1.3% and 2.6% ophthalmic solution (C-KAD) in improving visual function as assessed by contrast sensitivity; * To evaluate the safety and tolerability of two doses of EDTA ophthalmic solution (C-KAD); and * To determine the optimal clinical dose of EDTA ophthalmic solution (C-KAD) which to proceed into pivotal study(s).

Timeline

Start
2006-01-01
Primary completion
2006-12-31
Completion
2007-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject EDTA Unknown 1.3 % Other
Subject EDTA Unknown 2.6 % Other

Indications